The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Minimal residual disease (MRD) trials in colorectal cancer (CRC): An overview of a heterogeneous field.
 
Emerik Osterlund
Honoraria - Amgen
Consulting or Advisory Role - Amgen
Research Funding - Amgen (Inst); Lilly (Inst); Merck KGaA (Inst); Nordic Drugs (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Amgen; Merck KGaA; Nordic Drugs
 
Guglielmo Vetere
No Relationships to Disclose
 
Songwit Payapwattanawong
No Relationships to Disclose
 
Kristin Alfaro
Consulting or Advisory Role - Abbvie; SDP Oncology
 
Christine Parseghian
Consulting or Advisory Role - Amgen; Johnson & Johnson/Janssen
Research Funding - BioMed Valley Discoveries; Lilly; Verastem
 
Michael Overman
Consulting or Advisory Role - 3T BioSciences; Agenus; Bristol-Myers Squibb; Eisai; Janssen; Merck; Pfizer; Roche/Genentech; Simcere; Summit Therapeutics
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
Xiling Shen
Stock and Other Ownership Interests - iOrganBio Inc; OnVagus Inc; Viluxon Inc; Xilis
 
John Paul Shen
Stock and Other Ownership Interests - Agios; Syndax; Syndax
Consulting or Advisory Role - Engine Biosciences; NaDeNo Nanosciences
Research Funding - BostonGene; Ikena Oncology (Inst)
 
Van Morris
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; Exelixis; GlaxoSmithKline; Incyte; Pfizer
Research Funding - Bicara Therapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst)
 
Kanwal Raghav
Honoraria - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Consulting or Advisory Role - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Research Funding - Abbvie (Inst); Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Guardant Health (Inst); HiberCell (Inst); Innovent Biologics (Inst); Janssen (Inst); Merck Serono (Inst); Roche/Genentech (Inst); UCB (Inst); Xencor (Inst)
 
Arvind Dasari
Consulting or Advisory Role - HutcMed; Illumina/GRAIL; Personalis; SIRTIS; Takeda
Research Funding - Eisai (Inst); Guardant Health (Inst); Hutchison MediPharma (Inst); Merck (Inst); Natera (Inst); XENCOR (Inst)
Travel, Accommodations, Expenses - Hutchison MediPharma; Takeda
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Lutris; Navire
Consulting or Advisory Role - Alentis Therapeutics; AmMax Bio; Arcus Biosciences; AstraZeneca; AVEO; BeiGene; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Carina Biotech; Clasp Therapeutics; Cytovation; Dewpoint Therapeutics; EMD Serono; Erasca, Inc; Flame Biosciences; Frontier Medicines; Genentech; Harbinger Oncology, Inc; Ikena Oncology; Iterion Therapeutics; Kivu Biosciences; Marengo Therapeutics; Pfizer; Regeneron; Roche; SageMedic; SERVIER; Shionogi; T-Cypher Bio; Tachyon Therapeutics; Transcode; XAIRA Therapeutics; Zentalis; Zentalis
Research Funding - Boehringer Ingelheim; EMD Serono; Genentech; Pfizer; Roche; Zentalis